Estudia

• Reconèixer els elements essencials de la professió mèdica, que incloguin els principis ètics, les responsabilitats legals i l'exercici professional centrat en el pacient
• Desenvolupar la pràctica professional amb respecte pels altres professionals de la salut, adquirint habilitats de treball en equip
• Comunicar-se de manera efectiva i clara, tant oralment com per escrit, amb els pacients, els familiars, els mitjans de comunicació i altres professionals
• Conèixer, valorar críticament i saber utilitzar les fonts d'informació clínica i biomèdica per a obtenir, organitzar, interpretar i comunicar la informació científica i sanitària
• Saber utilitzar les tecnologies de la informació i la comunicació en les activitats clíniques, terapèutiques, preventives i d'investigació
• Tenir, en l'activitat professional, un punt de vista crític, creatiu, amb escepticisme constructiu i orientat a la recerca
• Garantir el coneixement adequat de la llengua anglesa, tant oral com escrita, tenint en compte les especificitats del registre mèdic per a poder comunicar-se eficaçment a la comunitat internacional científica i professional

1. Identify and assess the relationship between global consumption of medicines and prevalence of diseases

          1.1. Identify the most used medicines globally

          1.2. Assess the regional differences in drug consumption

          1.3. Identify the global diseases prevalence

          1.4. Asses the regional differences in the disease prevalence

          1.5. Relate the regional differences between drug consumption and diseases prevalence

2. Review which factors determine the selection of the therapeutic area in the development of medicines

          2.1. Identify the therapeutic areas and the diseases for which drugs have been developed in the last decade

          2.2. Describe the main characteristics of the diseases for which drugs have been developed in the last decade

          2.3. Explain which factors determine the selection of the therapeutic area in the development of medicines

          2.4. Review the concepts of orphan drug and orphan disease

3. Review the conflict between equity and commercial rights

          3.1. Review the concept of patent and the international agreements that regulate drug’s patentability and its exceptions

          3.2. Describe the concept of equity

          3.3. Explain the influence of commercial rights on medicines accessibility

          3.4. Analyse the conflict between commercial rights and right to access to medicines

4. Identify promotional strategies from drug development to drug marketing

          4.1. Identify promotional activities of the pharmaceutical firms and describe the existence of an ethical code of medicines promotion

          4.2. Recognize the concept of disease mongering and its interest in the drug development and drug consumption

          4.3. Identify and define the main characteristics of the different commercial sources of information on medicines

5. Review the criteria to authorize drugs in the European Union and its consequences

          5.1. Describe the criteria to authorize medicines in Europe and its effects on the market of medicines

          5.2. Describe the therapeutic innovation concept

          5.3. Examine the therapeutic innovation level of drugs recently marketed

          5.4. Recognize the meaning of the WHO essential drugs list

6. Identify the need to have open access to the information gathered on the effects of medicines

          6.1. Identify the accessibility to the premarketing clinical trials results in the main regulatory agencies

          6.2. Describe the concept of publication bias and its impact on the public knowledge regarding the efficacy and safety of drugs marketed

• Drugs for neglected disease initiative. Recuperat , a http://www.dndi.org/
• European Commission. Orphan medicinal products. Recuperat , a http://ec.europa.eu/health/human-use/orphan-medicines/index_en.htm
• Orphanet. The portal for rare diseases and orphan drugs. Recuperat , a http://www.orpha.net/consor/cgi-bin/index.php
• Federación Española de Enfermedades Raras. Recuperat , a http://www.enfermedades-raras.org/
• Laporte JR, Capellà D (2000). La investigación y el desarrollo de nuevos fármacos. Dins (Ed.), Diagnóstico y medicación. Entender las razones de cada tratamiento (, p. 42-73). Circulo de Lectores. Catàleg
• Laporte JR, Capellà D (2000). Los medicamentos en la sociedad. Dins (Ed.), Diagnóstico y medicación. Entender las razones de cada tratamiento (, p. 74-91). Circulo de Lectores. Catàleg
• Moynihan R, Heath I, Henry D. (2002). Selling sickness: the pharmaceutical industry and disease mongering.. BMJ, 324(), 886-91
• Motola D, De Ponti F, Poluzzi E et al. (2006). An Update on the first decade of the European centralized procedure: how many in. Br J Clin Pharmacol, 62(), 610-16. Recuperat , a http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885166/pdf/bcp0062-0610.pdf
• Farmaindustria (2010). Código español de buenas prácticas de promoción de medicamentos y de interrela. Recuperat , a http://www.autocontrol.es/pdfs/pdfs_codigos/farma_1067.pdf
• Pedrique B, Strub-Wourgaft N, Some C et al. (2013). The drug and vaccine landscape for neglected diseases (2000-11): a systematic as. Lancet Global Health, 1(), 371-79. Recuperat , a http://download.thelancet.com/pdfs/journals/langlo/PIIS2214109X13700780.pdf
• Llor C (2014). Medicamentos que matan y crimen organizado. Atención Primaria,, . Recuperat , a http://dx.doi.org/10.1016/j.aprim.2013.12.001

Activitats d'avaluació:

Evaluation has two parts (PBL session and PBL exam) and both of them must be passed independently.

Also, attendance to the workshops and lecture are compulsory.

PBL sessions evaluation will account for 50% of the module evaluation
Criteria:
- responsability (25%)
- learning abilities (25%)
- communication (25%)
- interpersonal relationships (25%)

PBL exam will account for the other 50% of the module evaluation
1st part criteria for each of the 4 explicative hypotesis
- relevance to the learning objectives (2%)
- relevance to the situation (2%)
- justification (6%)
2nd part criteria for each of the 2 questions
- acreditation of knowledge acquired within the question context (25%)
both parts criteria
- readibility and consciseness (10%)

Criteris específics de la nota «No Presentat»:
Not attending PBL sessions